Last Update: Oct 21, 2026 Real-world Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor (ARNi) Therapy in Lowering Blood Pressure in Hypertensive Patients in the United Arab Emirates ClinicalTrials.gov Identifier: [NCT07465666](https://clinicaltrials.gov/ct2/show/NCT07465666) Novartis Reference Number:CLCZ696AAE01 [See if you Pre-qualify](#trial-eligibility "See if you Pre-qualify") All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation. ## Study Description The aim of this study is to evaluate the real-world effectiveness of ARNi (sacubitril/valsartan) therapy and antihypertensive monotherapy in reducing blood pressure in hypertensive patients residing in the United Arab Emirates. Antihypertensive monotherapies will include angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), and calcium channel blockers (CCBs). Condition Hypertension Overall Status Recruiting Number of Participants500 Start Date Oct 15, 2026 Completion Date Aug 31, 2027 Gender All Age(s) 18 Years - 99 Years (Adult, Older Adult) ## Eligibility Criteria Inclusion criteria: 1\. Adult male or female patients (≥18 years). 2\. Patients with physician-diagnosed hypertension (as defined by international guidelines including the American Heart Association/American College of Cardiology \\\[AHA/ACC\\\] guidelines and/or the 2024 European Society of Cardiology \\\[ESC\\\] guidelines). 3\. Patients with documented office blood pressure ≥130/80 mmHg prior to initiating treatment (ARNi or monotherapy) or transitioning from monotherapy to ARNi. 4\. Patients who are either antihypertensive therapy naïve or currently receiving antihypertensive monotherapy (ACE inhibitor/ARB/CCB) with a physician-directed requirement to transition to ARNi. Note: Patients who transition from one monotherapy to another during the study are not eligible for inclusion. 5\. Patients willing to provide written informed consent to participate in the study. Exclusion criteria: 1\. Patients with malignant or severe hypertension (systolic blood pressure \\\[SBP\\\] ≥180 mmHg, diastolic blood pressure \\\[DBP\\\] ≥110 mmHg) at baseline. 2\. Patients with secondary causes of hypertension, as determined by the treating physician. 3\. Patients with a history of, or at risk of developing, angioedema. 4\. Patients with evidence of severe renal impairment (e.g., estimated glomerular filtration rate \\\[eGFR\\\] \\<30 mL/min/1.73 m\\^2). 5\. Pregnant or lactating women. 6\. Patients with serum potassium level ≥5.5 mmol/L at baseline. United Arab Emirates #### Novartis Investigative Site Recruiting Ras al-Khaimah,United Arab Emirates ## Worldwide Contacts If the location of your choosing does not feature any contact detail, please reach out using the information below. #### Novartis Pharmaceuticals Phone: [ +41613241111](tel:+41613241111) Email: